Finoriq research workspace
BIOMARIN PHARMACEUTICAL INC (BMRN) Institutional Holdings & 13F Ownership
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development. Review BMRN institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
- Company
- BIOMARIN PHARMACEUTICAL INC (BMRN)
- Ticker
- BMRN
- Market Cap
- $11.5B
- Latest Price
- $59.51
- Industry
- Biotech & Pharma
BIOMARIN PHARMACEUTICAL INC (BMRN) Top Institutional Holders
Top current 13F holders indexed for BIOMARIN PHARMACEUTICAL INC (BMRN). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Dodge & Cox (advisor level)CIK 0000200217 | $822.6M | 0.45% | Filing2026-05-14 |
| 2 | Viking Global InvestorsCIK 0001103804 | $398.9M | 1.1% | Filing2026-05-15 |
| 3 | Ray DalioCIK 0001350694 | $11.7M | 0.05% | Filing2026-05-15 |
| 4 | Joel GreenblattCIK 0001510387 | $9.8M | 0.03% | Filing2026-05-15 |
| 5 | Torray FundsCIK 0000098758 | $4.4M | 0.65% | Filing2026-05-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.